Quick Answer
Adaptimmune Therapeutics PLC reported Revenue (ASC 606) of $178.03 million for fiscal year 2024.
Adaptimmune Therapeutics PLC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $178.03M | +195.3% |
| 2023 | $60.28M | +122.0% |
| 2022 | $27.15M | +341.5% |
| 2021 | $6.15M | +55.4% |
| 2020 | $3.96M | +252.8% |
| 2019 | $1.12M | -98.1% |
| 2018 | $59.51M | +57.3% |
| 2017 | $37.83M | +166.5% |
| 2016 | $14.20M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $13.68M | -89.3% | +87.7% |
| March 31, 2025 | $7.29M | +28.3% | -82.2% |
| September 30, 2024 | $40.90M | +458.8% | -68.1% |
| June 30, 2024 | $128.23M | +2399.6% | +2158.4% |
| March 31, 2024 | $5.68M | -88.1% | -22.4% |
| September 30, 2023 | $7.32M | +4.5% | +42.7% |
| June 30, 2023 | $5.13M | -7.4% | -89.2% |
| March 31, 2023 | $47.60M | +1231.5% | +579.3% |
- Adaptimmune Therapeutics PLC showed an increase of +195.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2024 period, Adaptimmune Therapeutics PLC’s revenue (asc 606) has grown by 1153.9% (from $14.20 million to $178.03 million).
- The most recent figure is from Adaptimmune Therapeutics PLC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: